Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas
This is a phase 2 study to see how useful, safe, and tolerable an investigational drug
called ENMD-2076 is in treating patients with ovarian clear cell carcinomas.
ENMD-2076 is an oral drug that works by blocking certain enzymes called Aurora A and
tyrosine kinase from working. These enzymes are needed for cells to divide including cancer
cells. ENMD-2076 also works by stopping the growth of new blood vessels which would provide
the tumour with nutrients for it to grow. It is believed that by blocking Aurora A and
tyrosine kinase enzymes from working and stopping new blood vessels from growing, the tumours
may stop growing or shrink.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society